Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Chronic Pancreatitis I: Introduction

Chronic Pancreatitis I: Introduction

Chronic pancreatitis is a long-standing, relapsing inflammation of the pancreas, characterized by irreversible damage to the gland. It results in progressive destruction of the pancreatic parenchyma, fibrosis, and eventual loss of both exocrine and endocrine function. The disease may evolve gradually after multiple episodes of acute pancreatitis or develop independently.EtiologyChronic pancreatitis can arise from a variety of causes:Alcohol use is the leading cause, accounting for 70–80% of...

Chronic Pancreatitis I: Introduction

Chronic Pancreatitis I: Introduction

The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...

Chronic Pancreatitis II: Pathophysiology

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...

Chronic Pancreatitis II: Collaborative Care

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:

Acute Pancreatitis I: Introduction

Acute Pancreatitis I: Introduction

Acute pancreatitis is the sudden inflammation of the pancreas caused by the early activation of digestive enzymes, leading to the autodigestion of pancreatic tissue. This results in local inflammation and, in severe cases, systemic complications.EtiologyUnderstanding the underlying causes is crucial, as identifying the etiology guides treatment and anticipates complications. Acute pancreatitis can be triggered by various factors, typically grouped into the following clinical categories.Biliary...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Hospital pharmacists' knowledge about and attitudes towards dementia: a cross-sectional survey study.

The International journal of pharmacy practice·2026

Same author

Bleeding Risk With Apixaban Versus Rivaroxaban: A Reference Trial Emulation Predicting the Results of COBRRA-VTE and COBRRA-AF Using US Health Care Claims.

Circulation. Population health and outcomes·2026

Same author

Leveraging Real-World Evidence to Inform Regulatory, Clinical, and Coverage Decisions Related to Glucagon-Like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Annals of internal medicine·2026

Same author

A Plasmode Simulation-Based Bias Analysis for Residual Confounding by Unmeasured Variables Leveraging Information-Rich Subsets.

Pharmacoepidemiology and drug safety·2026

Same author

Stroke and Bleeding Risks With Non-Vitamin K Oral Anticoagulants in Nonvalvular Atrial Fibrillation.

JAMA network open·2026

Same author

Exploring the current status of pharmacist prescribing in Middle Eastern Arab countries: a scoping review.

International journal of clinical pharmacy·2026

Search research articles

Related Experiment Video

Updated: Jun 10, 2026

An Orthotopic Resectional Mouse Model of Pancreatic Cancer

An Orthotopic Resectional Mouse Model of Pancreatic Cancer

Published on: September 24, 2020

Statins and pancreatic cancer risk: a nested case-control study.

Marie C Bradley¹, Carmel M Hughes, Marie M Cantwell

¹Clinical and Practice Research Group, School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, Belfast BT9 7BL, Northern Ireland, UK. marie.bradley@qub.ac.uk

Cancer Causes & Control : CCC

|August 11, 2010

Summary

Statin use, prescribed for high cholesterol, showed no association with developing exocrine pancreatic cancer in a UK population study. This finding applies to various statin types, doses, and durations.

Related Experiment Videos

Last Updated: Jun 10, 2026

An Orthotopic Resectional Mouse Model of Pancreatic Cancer

An Orthotopic Resectional Mouse Model of Pancreatic Cancer

Published on: September 24, 2020

Area of Science:

Oncology
Pharmacology
Epidemiology

Background:

Pancreatic cancer is a significant health concern with complex risk factors.
Statins are widely prescribed for hypercholesterolemia, prompting investigation into their potential long-term effects.
Understanding the relationship between statin use and cancer risk is crucial for patient management.

Purpose of the Study:

To examine the association between statin utilization and the risk of developing exocrine pancreatic cancer.
To determine if statin dose, duration, or type influences pancreatic cancer risk.

Main Methods:

A nested case-control study design was employed using data from the UK General Practice Research Database (GPRD).
Pancreatic cancer cases were identified and matched with controls based on general practice, sex, and birth year.
Conditional logistic regression analysis was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for statin use.

Main Results:

The study included 1,141 pancreatic cancer cases and 7,954 controls.
Overall statin use was not associated with an increased or decreased risk of pancreatic cancer (OR 0.93; 95% CI, 0.76-1.14).
Neither the dose, duration, nor type of statin (simvastatin vs. atorvastatin) demonstrated a significant association with pancreatic cancer risk.

Conclusions:

Statin use for hypercholesterolemia management in the UK population is not linked to an elevated risk of exocrine pancreatic cancer.
The findings suggest that statins, at typical therapeutic doses, do not appear to increase pancreatic cancer risk.